Related Experiment Videos
Treatment of patients with transitional cell carcinoma of the urinary bladder with intravesical poly I: poly C
Abstract:
Considerable interest has been focused on the use of interferon (IFN) and IFN-inducers as antineoplastic agents in humans. The current report will focus on the effect of intravesical administration of Poly I: Poly C on NK activity in patients with TCC of the urinary bladder. NK cytotoxicity was measured in 14 patients with primary TCC, 8 patients received Poly I: Poly C and 5 other patients received intravesical thiotepa. Blood samples were obtained prior to and 48 h following each drug treatment. A variation in the initial NK level determined prior to treatment was observed in the different TCC patients: 5 patients treated with Poly I: Poly C and 5 patients treated with thiotepa exhibited low NK activity prior to treatment, whereas the other 3 patients who were treated with Poly I: Poly C had high initial NK levels. Following drug treatment it was shown that a significant elevation in the NK cytotoxicity was only observed in patients treated by intravesical Poly I: Poly C who had low NK activity prior to treatment. No such effect was observed in patients treated with thiotepa or in patients treated with Poly I: Poly C who exhibited a high NK activity prior to treatment.
Insights
Intravesical Poly I: Poly C boosts natural killer (NK) cell activity in bladder cancer patients with low initial NK levels. This immunotherapy effect was not seen with thiotepa or in patients with high baseline NK activity.
Area of Science:
- Immunology
- Oncology
- Pharmacology
Background:
- Interferon (IFN) and its inducers are explored as cancer treatments.
- Intravesical Poly I: Poly C is investigated for its immunomodulatory effects in urothelial carcinoma.
Purpose of the Study:
- To evaluate the impact of intravesical Poly I: Poly C on natural killer (NK) cell activity in patients with transitional cell carcinoma (TCC) of the urinary bladder.
- To compare the effects of Poly I: Poly C with thiotepa on NK cell activity.
Main Methods:
- 14 patients with primary TCC were enrolled.
- 8 patients received intravesical Poly I: Poly C, and 5 received intravesical thiotepa.
- Blood samples were collected pre-treatment and 48 hours post-treatment to measure NK cytotoxicity.
Main Results:
- A significant elevation in NK cytotoxicity was observed exclusively in patients treated with intravesical Poly I: Poly C who had low baseline NK activity.
- No significant increase in NK activity was noted in patients treated with thiotepa.
- Patients treated with Poly I: Poly C who had high initial NK levels did not show a significant increase in NK cytotoxicity.
Conclusions:
- Intravesical Poly I: Poly C demonstrates a potential to enhance NK cell-mediated immune response in TCC patients with pre-existing low NK activity.
- The efficacy of Poly I: Poly C as an immunotherapeutic agent for TCC may be dependent on the patient's baseline immune status.
- Thiotepa did not show a similar NK-boosting effect, suggesting a distinct mechanism of action.